Mckesson Corporation  (MCK)
Other Ticker:  
Price: $438.6600 $0.42 0.096%
Day's High: $441.21 Week Perf: 2.66 %
Day's Low: $ 435.91 30 Day Perf: 4.12 %
Volume (M): 962 52 Wk High: $ 444.80
Volume (M$): $ 421,772 52 Wk Avg: $383.14
Open: $437.02 52 Wk Low: $331.75

 Market Capitalization (Millions $) 59,921
 Shares Outstanding (Millions) 137
 Employees 75,000
 Revenues (TTM) (Millions $) 284,040
 Net Income (TTM) (Millions $) 3,910
 Cash Flow (TTM) (Millions $) 297
 Capital Exp. (TTM) (Millions $) 582

Mckesson Corporation
McKesson Corporation, is a Fortune 16 corporation providing supply, information and care management products and services designed to reduce costs and improve quality across the healthcare industry.
We conduct our business through three segments. Through our Pharmaceutical Solutions segment, we are a leading distributor of ethical and proprietary drugs, and health and beauty care products throughout North America.

   Company Address: 6555 State Hwy 161 Irving 75039 TX
   Company Phone Number: 446-4800   Stock Exchange / Ticker: NYSE MCK
   MCK is expected to report next financial results on October 31, 2023. Next quarterly dividend pay out on October 02, 2023.

Customers Net Income fell by MCK's Customers Net Profit Margin fell to

-20.54 %

2.22 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABC        1.24% 
CAH        0.9% 
BDX        0.24% 
CTSH   -0.87%    
DHR   -2.13%    
• View Complete Report

Can B Corp

Can B Corp Reports Significant Losses of $-0.37 per Share, Reflecting Struggles in the Current Market

As a seasoned investor, I analyze financial reports rigorously, looking for patterns and insights that would aid in making informed decisions. This article aims to interpret the latest financial results of Can B Corp, shedding light on its dwindling performance and the subsequent impact on its share prices.
The financial interval ending June 30, 2023, reveals a concerning loss for Can B Corp. The company reported a loss of $-0.37 per share, showing a slight improvement over the previous year's loss of $-0.49 per share. However, it is a decline from the previous financial reporting period, where the loss stood at $-0.36 per share. Such losses illustrate the challenges faced by Can B Corp in the current market.

Stemtech Corporation

Stemtech Corporation Defies the Odds with Remarkable Resurgence in Revenue during Challenging Times

Stemtech Corporation, a company operating in the [relevant industry], has experienced significant fluctuations in its share prices over the last five trading days. With a downward trend of -7.21%, the company's shares now reflect a year-to-date performance decrease of -48.52%. These figures suggest a challenging period for Stemtech, raising questions about the future implications for the company.
1. Break-even in Q2 2023:
During the fiscal second quarter of 2023, Stemtech Corporation reached a break-even point of $0.00 per share, a significant improvement compared to the previous year's loss of $-0.56 per share. However, compared to the prior quarter's loss of $-0.04 per share, there seems to be a minimal improvement. This break-even situation indicates that Stemtech is making efforts to improve its financial performance.

Trxade Health Inc

1. Trxade Health Inc: Revenue Plummets in Q2 of 2023, Sparking Concerns for Company's Future2. Breaking News: Trxade Health Inc Sees Significant Dip in Q2 2023 Revenue, Raises Alarm Bells

Trxade Health Inc, a healthcare services company that operates an online marketplace for pharmaceuticals, recently released its second-quarter 2023 financial report. Unfortunately, the report shows a weak business performance, resulting in a significant increase in losses compared to the same period last year.
One of the key metrics that highlights this decline is the net loss per share, which surged to $-2.90 from $-0.13. This indicates a substantial decrease in profitability for the company. Additionally, the revenue for the second quarter fell by 29.009% to $2.25 million, compared to $3.17 million in the previous year. This decline in revenue further emphasizes the challenges faced by Trxade Health Inc during this period.

Bimi International Medical Inc

BIMI Reports Striking Revenue Slump Amidst Recent Fiscal Period, Raising Concerns Over Bimi International Medical Inc's Financial Position

BIMI Reports Disappointing Financial Results for Q1 2023: Future Performance Remains Uncertain
Bimi International Medical Inc (BIMI) recently disclosed its financial results for the interval ending March 31, 2023, which painted a disappointing picture for the company. Revenue experienced a significant decline of -36.299% to $3.20 million, while net loss per share reached $-0.23, as compared to $-0.27 in the first quarter of 2022.
This downturn stands in contrast to the remainder of the Pharmacy Services and Retail Drugstore sector, which saw a revenue improvement in the first quarter of 2023. In the previous reporting season, BIMI's EPS fell from $6.39 per share, while revenue turned positive from $-34,046.66 million.

Sharing Services Global Corporation

Sharing Services Global Corporation (SHRV) Faces Steep Revenue Decline and Net Loss ? What's Next for the Company?

Sharing Services Global Corporation (SHRV) recently released its first quarter financial report for 2024, which highlighted concerning figures in terms of revenue and net loss per share. However, it is important to compare these figures with previous periods and industry peers to gain a more comprehensive understanding of the company's situation. This article will examine the implications of SHRV's financial results and discuss how they may impact the company moving forward.
1. Revenue Meltdown and Net Loss Per Share:
SHRV's first quarter of 2024 saw revenue decline by a significant -45.733% to $2.88 million. Simultaneously, the net loss per share remained stagnant at $-0.01, which was identical to the previous financial period ending in June 2022. These figures indicate a worrying trend and pose a challenge for SHRV to reverse the declining revenue and bring about profitability.


Mckesson's Segments
U.S. Healthcare direct distribution & services
 Segment     of total Revenue
Canada distribution & services
 Segment     of total Revenue
Pharmaceutical Solutions
 Segment     of total Revenue
Medical-Surgical Solutions
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Mckesson does not provide revenue guidance.

Earnings Outlook
Mckesson Corporation issued annual earnings guidance on

Geographic Revenue Dispersion
United States


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com